Effects of ipragliflozin and sitagliptin on serum lipid and apolipoprotein profiles in type 2 diabetes

According to a recent study, ipragliflozin may have an anti-atherogenic effect through modulation of apoE(Apolipoprotein E) and HDL-C(High-density lipoprotein cholesterol) when compared to sitagliptinthrough apo B48 (Apolipoprotein B48) and TG(Triglycerides),CII, and CIII in type 2 diabetic patients. The results of this study were published in the journal, Cardiovascular Diabetology.

The SUCRE study was a multicenter, open-label, randomized, controlled trial that included 20-74 years old patients with type 2 diabetes. These patients had serum triglyceride levels of 120-399 mg/dL and HbA1c levels of 7.0-10.5% and/or were on oral hypoglycemic agents. These subjects were randomized to receive either 50 mg/day of ipragliflozin (n=77) or 50 mg/day of sitagliptin (n=83). The clinical parameters were measured at 0, 1, 3, and 6 months following the treatment.

At the end of the study, both ipragliflozin and sitagliptin showed reduced levels of fasting plasma glucose, HbA1c, and glycoalbumin. While ipragliflozin increased HDL-C while decreasing apo E, sitagliptin increased LDL-C (Low-density lipoprotein cholesterol) while decreasing TG, CII, CIII, and apo B48. For HDL-C and apo B48, the differences between treatments were significant but for apo A1, they were almost significant. Additionally, ipragliflozin reduced blood pressure, body weight, uric acid, serum liver enzymes, and leptin and increased serum ketones.

Based on the above results, it can be concluded that although ipragliflozin and sitagliptin may affect glycemic parameters in a similar manner, their effects on serum lipid and apolipoprotein profiles may be different. Therefore, ipragliflozin may have an anti-atherogenic effect in patients with type 2 diabetes compared to sitagliptin through modulation of HDL-C and apo E.